ECONOMIC EVALUATION OF THE USE OF IBUPROFEN AS AN NSAID WITH ANALGESIC ACTION FOR THE TREATMENT OF PATIENTS WITH ACUTE PAIN
Author(s)
Gonzalez E1, Morales E1, Figueroa A2, Gutierrez M2, Ortiz M2
1Progela S.A. de C.V., Mexico City, Mexico, 2Pharmamanagement EAS S de RL de CV, Cuidad de México, Mexico
OBJECTIVES: To perform a complete economic evaluation of Ibuprofen as an NSAID with analgesic action for the treatment of patients with acute pain, compared to the therapeutic alternatives considered in the Basic Medication Formulary of IMSS (CBMIMSS for its acronym in Spanish). METHODS: A systematic review of the use of Ibuprofen as a non-steroidal anti-inflammatory with analgesic action for the treatment of acute pain was carried out. A meta-analysis was necessary to verify the therapeutic similarity of Ibuprofen vs available CBMIMSS comparators. Given the therapeutic similarity of these options, a cost minimization was the economic analysis performed, in addition to a budget impact analysis (BIA). RESULTS: The cost of treatment with ibuprofen represents one-third of the cost of treating patients with acute pain with the most expensive alternative (Lysine Clonixinate) $5.88 vs $18.53 (MXN), while the difference in cost vs Paracetamol is $4.27 for the presentation of 200mg and $2.93 for the presentation of 400mg. The BIA showed that the introduction of Ibuprofen would generate a saving of $23,652.27 in the first year; on average it will have a potential saving of $73,301.74 and an average saving percentage of 0.00015583% of the total budget. CONCLUSIONS: Based on the results found in the present study, it is possible to conclude that the use of Ibuprofen 400mg, is a cost-saving alternative in compatison to the therapeutic alternatives available in the CBMIMSS such as paracetamol, acetyl salicylic acid, Ketorolac, Lysine, clonixinate and metamizole.
Conference/Value in Health Info
2017-05, ISPOR 2017, Boston, MA, USA
Value in Health, Vol. 20, No. 5 (May 2017)
Code
PSY73
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Systemic Disorders/Conditions